TISIDB

Summary
Symbol	NUDT5
Name	nudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases	hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location	10p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00293 NUDIX domain
Function	Enzyme that can either act as an ADP-sugar pyrophosphatase in absence of diphosphate or catalyze the synthesis of ATP in presence of diphosphate (PubMed:27257257). In absence of diphosphate, hydrolyzes with similar activities various modified nucleoside diphosphates such as ADP-ribose, ADP-mannose, ADP-glucose, 8-oxo-GDP and 8-oxo-dGDP (PubMed:10567213, PubMed:10722730, PubMed:19699693, PubMed:21389046, PubMed:17052728). Can also hydrolyze other nucleotide sugars with low activity (PubMed:19699693, PubMed:21389046). In presence of diphosphate, mediates the synthesis of ATP in the nucleus by catalyzing the conversion of ADP-ribose to ATP and ribose 5-phosphate. Nuclear ATP synthesis takes place when dephosphorylated at Thr-45 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257). Does not play a role in U8 snoRNA decapping activity (By similarity). Binds U8 snoRNA (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0005996 monosaccharide metabolic process GO:0006014 D-ribose metabolic process GO:0006338 chromatin remodeling GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009123 nucleoside monophosphate metabolic process GO:0009126 purine nucleoside monophosphate metabolic process GO:0009132 nucleoside diphosphate metabolic process GO:0009134 nucleoside diphosphate catabolic process GO:0009141 nucleoside triphosphate metabolic process GO:0009144 purine nucleoside triphosphate metabolic process GO:0009150 purine ribonucleotide metabolic process GO:0009161 ribonucleoside monophosphate metabolic process GO:0009167 purine ribonucleoside monophosphate metabolic process GO:0009185 ribonucleoside diphosphate metabolic process GO:0009191 ribonucleoside diphosphate catabolic process GO:0009199 ribonucleoside triphosphate metabolic process GO:0009205 purine ribonucleoside triphosphate metabolic process GO:0016052 carbohydrate catabolic process GO:0019303 D-ribose catabolic process GO:0019321 pentose metabolic process GO:0019323 pentose catabolic process GO:0019439 aromatic compound catabolic process GO:0034655 nucleobase-containing compound catabolic process GO:0034656 nucleobase-containing small molecule catabolic process GO:0042278 purine nucleoside metabolic process GO:0044270 cellular nitrogen compound catabolic process GO:0044282 small molecule catabolic process GO:0044723 single-organism carbohydrate metabolic process GO:0044724 single-organism carbohydrate catabolic process GO:0046034 ATP metabolic process GO:0046128 purine ribonucleoside metabolic process GO:0046365 monosaccharide catabolic process GO:0046434 organophosphate catabolic process GO:0046700 heterocycle catabolic process GO:1901292 nucleoside phosphate catabolic process GO:1901361 organic cyclic compound catabolic process GO:1901657 glycosyl compound metabolic process GO:1990966 ATP generation from poly-ADP-D-ribose
Molecular Function	GO:0000287 magnesium ion binding GO:0016779 nucleotidyltransferase activity GO:0017110 nucleoside-diphosphatase activity GO:0019144 ADP-sugar diphosphatase activity GO:0030515 snoRNA binding GO:0044715 8-oxo-dGDP phosphatase activity GO:0047631 ADP-ribose diphosphatase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00230 Purine metabolism
Reactome	R-HSA-1430728: Metabolism R-HSA-15869: Metabolism of nucleotides R-HSA-2393930: Phosphate bond hydrolysis by NUDT proteins

Summary
Symbol	NUDT5
Name	nudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases	hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location	10p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NUDT5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NUDT5
Name	nudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases	hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location	10p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NUDT5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.78	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NUDT5
Name	nudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases	hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location	10p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NUDT5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.196	0.429
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.209	0.929
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.187	0.914
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.415	0.241
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.09	0.957
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.829	0.703
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.101	0.767
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.182	0.895
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.001	0.999
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.011	0.995
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.012	0.997
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.229	0.00242

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NUDT5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	NUDT5
Name	nudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases	hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location	10p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NUDT5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NUDT5
Name	nudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases	hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location	10p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NUDT5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NUDT5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NUDT5
Name	nudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases	hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location	10p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NUDT5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NUDT5
Name	nudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases	hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location	10p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NUDT5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NUDT5
Name	nudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases	hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location	10p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NUDT5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NUDT5
Name	nudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases	hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location	10p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NUDT5 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NUDT5